#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...

The fully human anti-TNF-α antibody adalimumab (Humira; Abbott) was approved by the FDA in 2007. This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...